Pemetrexed for the treatment of non-small-cell lung cancer

  • Technology appraisal guidance
  • TA124
  • Published: 
Download guidance (PDF)

6 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG):

  • Bagust A et al Pemetrexed for the treatment of relapsed non-small cell lung cancer, September 2006.

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope. Companies or sponsors were also invited to make written submissions. Professional or specialist, and patient or carer groups, gave their expert views on pemetrexed by providing a written statement to the Committee. Companies or sponsors, and professional or specialist, and patient or carer groups, have the opportunity to appeal against the final appraisal determination.

Company or sponsor:

  • Eli Lilly and Company Ltd.

Professional or specialist, and patient or carer groups:

  • British Thoracic Oncology Group

  • British Thoracic Society

  • Cancer Networks Pharmacists Forum

  • Cancer Research UK

  • CancerBackup

  • Department of Health

  • Roy Castle Lung Cancer Foundation

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • Tenovus Cancer Information Centre

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • British Thoracic Oncology Group

  • MRC CTU - Lung Cancer and Mesothelioma Group

  • National Collaborating Centre for Cancer

  • NHS Quality Improvement Scotland

  • Roche Products Ltd.

  • Sanofi-Aventis

The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on pemetrexed by providing oral evidence to the Committee.

  • Dr Jesme Baird, Director of Patient Care, nominated by the Roy Castle Lung Cancer Foundation – patient expert

  • Professor David R Ferry, Medical Oncologist, New Cross Hospital, Wolverhampton, nominated by the Royal College of Physicians – clinical specialist

  • Dr Mary O'Brien, Consultant Medical Oncologist, Institute of Cancer Research, nominated by the Institute of Cancer Research – clinical specialist

  • Dr Elizabeth Sawicka, Consultant, Princess Royal University Hospital, nominated by The British Thoracic Society – clinical specialist